U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug
© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo AMGN -2.85% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully to:
+ Add another position Close JNJ +0.89% Add to/Remove from Watchlist Add to Watchlist Add Position
Position added successfully to:
+ Add another position Close
(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Amgen (NASDAQ:AMGN)'s biosimilar version of Johnson & Johnson (NYSE:JNJ)'s blockbuster psoriasis treatment, Stelara, for multiple inflammatory diseases.
Despite the FDA approval, Amgen's treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.
Biosimilars are close copies of complex biological drugs.
Stelara, introduced in 2009, has been J&J's top-selling drug since 2019, with sales reaching $9.7 billion in 2022.
U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug
Chinese services activity rebounds in Nov as demand improves- Caixin PMI
Analysis-Asian power generation gets cleaner, even as coal emissions rise
Stellantis, CATL plan factory in Europe to make cheaper EV batteries
Nvidia’s Asian suppliers cautiously advance as qtrly results loom
Oil retreats on caution ahead of OPEC+ meeting
Nippon Steel lifts annual outlook on improved first-half margins
Exclusive-UK rips up state guarantees on nearly 1 billion pounds of COVID loans
IMF staff recommends further tightening of monetary policy in Australia
